« Previous
Next »
Titles
- 30-Day notices, 135-day premarket approval (PMA) supplements and 75-day humanitarian device exemption (HDE) supplements for manufacturing method or process changes: guidance for industry and Food and Drug Administration staff1
- A few states fell short in timely investigation of the most serious nursing home complaints: 2011-20151
- A premium support system for Medicare: updated analysis of illustrative options1
- ACOs' strategies for transitioning to value-based care: lessons from the Medicare shared savings program1
- ANDA submissions--amendments to abbreviated new drug applications under GDUFA1
- Acceptance and filing reviews for premarket approval applications (PMAs): guidance for industry and Food and Drug Administration staff1
- Acne vulgaris: establishing effectiveness of drugs intended for treatment1
- Adaptive designs for clinical trials of drugs and biologics1
- Administrative procedures for CLIA categorization: guidance for industry and Food and Drug Administration staff1
- Advancement of emerging technology applications for pharmaceutical innovation and modernization1
- Adverse events in long-term-care hospitals: national incidence among Medicare beneficiaries1
- Affordable Care Act: IRS should mitigate limitations of data to be used for the age and gender adjustment for the tax on high-cost health plans : report to Congressional committees1
- Air ambulance: data collection and transparency needed to enhance DOT oversight : report to the Committee on Transportation and Infrastructure, House of Representatives1
- Alaska State Medicaid Fraud Control Unit: 2016 onsite review1
- Allergic rhinitis: developing drug products for treatment1
- Amyotrophic lateral sclerosis: developing drugs for treatment1
- An analysis of private-sector prices for hospital admissions1
- An analysis of private-sector prices for physicians' services1
- An evaluation of CBO's past outlay projections1
- Anthrax: developing drugs for prophylaxis of inhalational anthrax1